Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Business Segments — General And Administrative Expense, Personnel

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — General and administrative, excluding personnel expenses
$4.61M+339%
Immunovant, Inc. logo
IMVTReportable Segment — Personnel-related general and administrative
$10.13M+8.9%
Global Water Resources logo
GWRSReportable Segment — Personnel costs - general and administrative
$2.36M+7.4%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Commercial Selling, General And Administrative Personnel Expenses
$20.04M+65.7%
HCI Group logo
HCIGeneral And Administrative Personnel Expense
$23.95M+19.8%
HCI Group logo
HCIGeneral And Administrative Personnel Expense
$23.95M+19.8%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inhibrx:GeneralAndAdministrativeExpensePersonnel.

The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0002007919-26-000027
Line itemTHREE MONTHS ENDEDMARCH 31, 2026THREE MONTHS ENDEDMARCH 31, 2025
Other research and development(2,906)(3,153)
Total research and development expense(25,217)(36,877)
General and administrative expense
Personnel(3,646)(3,777)
Other general and administrative(2,064)(2,247)
Total general and administrative expense(5,710)(6,024)
Other expense(2,514)(410)
Segment and consolidated net loss$(33,441)$(43,311)

Item 1. Financial Statements (unaudited)

FAQ

What is Inhibrx Biosciences, Inc.'s business segments — general and administrative expense, personnel?
Inhibrx Biosciences, Inc. (INBX) reported business segments — general and administrative expense, personnel of $3.65M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s business segments — general and administrative expense, personnel changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — general and administrative expense, personnel decreased by 3.5% year-over-year, from $3.78M to $3.65M.
What does business segments — general and administrative expense, personnel mean?
This metric represents the compensation and benefits for administrative, legal, and executive staff who support the company's corporate functions. It reflects the overhead required to manage the business operations outside of direct research activities. Tracking this helps evaluate the company's administrative efficiency and corporate scaling.

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — general and administrative expense, personnel.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude